COVID-19 vaccine news continues to dominate headlines as candidates from several companies move closer to obtaining emergency use authorization from the Food and Drug Administration. Also on the drug approval front, tech giant Palantir and the FDA entered into a $44 million deal for the agency to use the ... READ MORE >
CHART OF THE DAY: Vaccine doses for the global population
With the U.S. Food and Drug Administration set to review Pfizer and BioNTech’s COVID-19 vaccine this week for emergency use authorization and Moderna’s vaccine next week, we have passed the “if” phase of questions around the vaccine. Now, the focus turns to the “when and how” of distribution. The ... READ MORE >
Looking ahead: next steps for the economy after Pfizer’s promising vaccine news
Pfizer and German biotech firm BioNTech’s Monday announcement that their COVID-19 vaccine candidate has shown to be more than 90% effective in preliminary results from an ongoing trial is a much needed win in the fight against the pandemic. It carries significant economic implications regarding the ... READ MORE >
CHART OF THE DAY: The race to find a coronavirus vaccine
Scientists have been working at a blistering pace to shorten the vaccine development cycle from years to months in order to take a coronavirus vaccine to market. With more than 190 such vaccines in development, there are several leading the pack. Two trials, by AstraZeneca and Johnson & Johnson, ... READ MORE >
The search for a safe and effective coronavirus vaccine
Regardless of race, religion or socioeconomic status, one thing most, if not all, Americans can agree on is that we are tired of the pandemic and the economic, health and political fallout we have collectively experienced from it. And while there may be disagreement about the best way to approach the ... READ MORE >
More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine
Picture this scenario: Researchers at a biotech company are working tirelessly on a potential coronavirus vaccine and planning to start a phase three clinical trial soon. This work results in more visibility for the company, and an influx of capital investment. But with that greater visibility and ... READ MORE >
No vaccine, no recovery: The long road back
It is becoming quite clear that absent an accessible and widely distributed vaccine, there will be no complete economic recovery. What originally was thought to be a 15 week problem has quickly evolved into something that looks more like a 15-month challenge. The premature reopening of the U.S. economy ... READ MORE >
Trump administration identifies 5 companies for government support in vaccine effort
Drug developers, academic institutions and government agencies across the globe are investigating more than 100 potential vaccines for the coronavirus. The Trump administration on Wednesday identified a handful of organizations that it believes are the most likely to produce a viable vaccine candidate, ... READ MORE >
Coronavirus pandemic highlights importance of life sciences industry
While the coronavirus pandemic has slowed growth in the life sciences sector this year, it has also highlighted the importance of the biotech and pharmaceutical industries as the whole world battles the COVID-19 disease and its impacts. This industry focus could have a lasting impact in shifting consumer ... READ MORE >
Life sciences industry growth was on a strong trajectory. Then the coronavirus pandemic hit.
Strong consumer spending, historically low unemployment and an easing of trade tensions with China initially fueled optimism early in the year for a 2020 bull market. But as the coronavirus pandemic has upended the global economy, uncertainty and disruption have replaced that once sunny outlook, and the ... READ MORE >